Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001193471 | SCV001362332 | likely pathogenic | Sulfate transporter-related osteochondrodysplasia | 2019-11-18 | criteria provided, single submitter | clinical testing | Variant summary: SLC26A2 c.145delA (p.Arg49AspfsX40) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 4e-06 in 251140 control chromosomes (gnomAD). c.145delA has been reported in the literature in at least one compound heterozygous individual affected with Sulfate Transporter-Related Osteochondrodysplasia (Atelosteogenesis Type II) (Dwyer_2010). These data do not allow clear conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Baylor Genetics | RCV001828598 | SCV004201777 | pathogenic | Achondrogenesis, type IB | 2023-11-23 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001828598 | SCV002081845 | likely pathogenic | Achondrogenesis, type IB | 2020-12-07 | no assertion criteria provided | clinical testing |